LBA3 Randomized phase III study of selpercatinib versus cabozantinib or vandetanib in advanced, kinase inhibitor-naïve, RET-mutant medullary thyroid cancer

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 34; p. S1338
Main Authors Hadoux, J., Elisei, R., Brose, M.S., Hoff, A., Robinson, B., Gao, M., Jarzab, B., Isaev, P., Kopeckova, K., Wadsley, J., Führer, D., Keam, B., Sherman, E.J., Tahara, M., Hu, M.I., Lin, Y., Maeda, P., Wirth, L.J., Capdevila Castillon, J.
Format Journal Article
LanguageEnglish
Published Elsevier Ltd 01.10.2023
Online AccessGet full text

Cover

More Information
ISSN:0923-7534
1569-8041
DOI:10.1016/j.annonc.2023.10.103